Chelsea Therapeutics International Ltd. Resources | BNET
On TechRepublic: 19 words you don't want in your resume

BNET Industries

Chelsea Therapeutics International Ltd. (CHTP) is in the Pharma Industry

Profit
Dec 31 2007
($15.0M)
Market Cap
Jul 23 2008
$192.8M

Latest News and Analysis

Additional Resources

  • AGT, SGN, AGIX, CHTP, SOLM, BZLFY Have Been Removed From Naked Short List Today.

    M2 PRESSWIRE-1 April 2008-BUYINS.NET: AGT, SGN, AGIX, CHTP, SOLM, BZLFY Have Been Removed From Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE...

    Articles 2008-04-01

  • NRF, WAL, CHTP, EFSC, GTOP, MCEL Have Been Added To Naked Short List Today.

    M2 PRESSWIRE-1 April 2008-BUYINS.NET: NRF, WAL, CHTP, EFSC, GTOP, MCEL Have Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE...

    Articles 2008-04-01

  • NRF, WAL, CEGE, CHTP, EFSC, GTOP Have Been Added To Naked Short List Today.

    M2 PRESSWIRE-24 March 2008-BUYINS.NET: NRF, WAL, CEGE, CHTP, EFSC, GTOP Have Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:24032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE...

    Articles 2008-03-24

  • CHELSEA THERAPEUTICS INITIATES PHASE II TRIAL OF CH-1504.(Medical condition overview)

    Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has initiated enrollment and patient dosing in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-1504 against methotrexate MTX in rheumatoid arthritis RA patients. CH-1504, a non-metabolized antifolate,...

    Articles 2008-03-01

  • Incorporated: 2002
  • CEO: Dr. Simon Pedder Ph.D.

Chelsea Therapeutics International is a development stage pharmaceutical company. Co. is developing two platform technologies that each consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases. These platforms include Co.'s key product candidate, CH-1504, an orally molecule with potent anti-inflammatory, autoimmune and anti-tumor properties and I-3D portfolio that is being co-developed with Active Biotech AB. Co. is also developing droxidopa, an orally active synthetic precursor of norepinephrine for the treatment of symptomatic orthostatic hypotension, freezing gait in Parkinson's disease, and for intra dialytic hypotension.

Key Competitors

Chelsea Therapeutics International Ltd. Company Info

Board of Directors

Dr. Kevan Clemens Ph.D.

Chairman

Dr. Simon Pedder Ph.D.

Dr. Johnson Y.N. Lau M.D.

Dr. Michael Weiser M.D., Ph

Dr. Roger G. Stoll Ph.D.

Dr. Norman Hardman Ph.D.

Dr. William D. Schwieterman M.D.

Contact Information

13950 Ballantyne Corporate Place, Suite 325

Charlotte, NC

http://www.chelsearx.com

704 341-1516

NAICS Code

Biological Product (except Diagnostic) Manufacturing: 325414